Advanced

Estrogen receptor β1 in diffuse large B-cell lymphoma growth and as a prognostic biomarker

Hasni, Muhammad Sharif LU ; Berglund, Mattias; Yakimchuk, Konstantin; Guan, Jiyu; Linderoth, Johan LU ; Amini, Rose-Marie; Enblad, Gunilla and Okret, Sam (2017) In Leukemia & lymphoma 58(2). p.418-427
Abstract

Diffuse large B-cell lymphoma (DLBCL) shows a higher incidence in males versus females. Epidemiological studies have shown that female gender is a favorable prognostic factor, which may be explained by estrogens. Here we show that when grafting human DLBCL cells to immunocompromised mice, tumor growth in males is faster. When treating mice grafted with either germinal center or activated B-cell like DLBCL cells with the selective estrogen receptor β (ERβ) agonist diarylpropionitrile, tumor growth was significantly inhibited. Furthermore, nuclear ERβ1 expression analysis in primary DLBCL’s by immunohistochemistry revealed expression in 89% of the cases. Nuclear ERβ1 expression was in a univariate and multivariate analysis, an independent... (More)

Diffuse large B-cell lymphoma (DLBCL) shows a higher incidence in males versus females. Epidemiological studies have shown that female gender is a favorable prognostic factor, which may be explained by estrogens. Here we show that when grafting human DLBCL cells to immunocompromised mice, tumor growth in males is faster. When treating mice grafted with either germinal center or activated B-cell like DLBCL cells with the selective estrogen receptor β (ERβ) agonist diarylpropionitrile, tumor growth was significantly inhibited. Furthermore, nuclear ERβ1 expression analysis in primary DLBCL’s by immunohistochemistry revealed expression in 89% of the cases. Nuclear ERβ1 expression was in a univariate and multivariate analysis, an independent prognostic factor for adverse progression-free survival in Rituximab-chemotherapy treated DLBCL (p = 0.02 and p = 0.04, respectively). These results suggest that estrogen signaling through ERβ1 is an interesting future therapeutic target for treatment of DLBCL, and that ERβ1 expression can be used as a prognostic marker.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Estrogen, gender difference, immunohistochemistry, lymphoma growth, receptor expression
in
Leukemia & lymphoma
volume
58
issue
2
pages
10 pages
publisher
Taylor & Francis
external identifiers
  • scopus:84976354228
  • wos:000388601000021
ISSN
1042-8194
DOI
10.1080/10428194.2016.1193853
language
English
LU publication?
yes
id
f10d691f-2515-4674-94e7-dbcd6a29a69d
date added to LUP
2017-02-06 08:35:56
date last changed
2018-04-22 04:26:12
@article{f10d691f-2515-4674-94e7-dbcd6a29a69d,
  abstract     = {<p>Diffuse large B-cell lymphoma (DLBCL) shows a higher incidence in males versus females. Epidemiological studies have shown that female gender is a favorable prognostic factor, which may be explained by estrogens. Here we show that when grafting human DLBCL cells to immunocompromised mice, tumor growth in males is faster. When treating mice grafted with either germinal center or activated B-cell like DLBCL cells with the selective estrogen receptor β (ERβ) agonist diarylpropionitrile, tumor growth was significantly inhibited. Furthermore, nuclear ERβ1 expression analysis in primary DLBCL’s by immunohistochemistry revealed expression in 89% of the cases. Nuclear ERβ1 expression was in a univariate and multivariate analysis, an independent prognostic factor for adverse progression-free survival in Rituximab-chemotherapy treated DLBCL (p = 0.02 and p = 0.04, respectively). These results suggest that estrogen signaling through ERβ1 is an interesting future therapeutic target for treatment of DLBCL, and that ERβ1 expression can be used as a prognostic marker.</p>},
  author       = {Hasni, Muhammad Sharif and Berglund, Mattias and Yakimchuk, Konstantin and Guan, Jiyu and Linderoth, Johan and Amini, Rose-Marie and Enblad, Gunilla and Okret, Sam},
  issn         = {1042-8194},
  keyword      = {Estrogen,gender difference,immunohistochemistry,lymphoma growth,receptor expression},
  language     = {eng},
  month        = {02},
  number       = {2},
  pages        = {418--427},
  publisher    = {Taylor & Francis},
  series       = {Leukemia & lymphoma},
  title        = {Estrogen receptor β1 in diffuse large B-cell lymphoma growth and as a prognostic biomarker},
  url          = {http://dx.doi.org/10.1080/10428194.2016.1193853},
  volume       = {58},
  year         = {2017},
}